Vir Biotechnology Taps Oncology Veteran David Liu as Chief Medical Officer
Event summary
- David Liu, M.D., Ph.D., appointed as Executive Vice President and Chief Medical Officer of Vir Biotechnology, effective October 12, 2026.
- Liu brings over 25 years of experience in immuno-oncology, including leadership roles at Nuvation Bio, 3D Medicines, Celgene, Bristol Myers Squibb, and AstraZeneca.
- Vir Biotechnology is advancing a Phase 3 program for chronic hepatitis delta and a pipeline of cancer immunotherapies.
- Liu will oversee clinical development, medical affairs, and regulatory affairs functions.
The big picture
Vir Biotechnology's appointment of David Liu as CMO underscores its strategic focus on advancing its immuno-oncology pipeline. Liu's extensive experience in securing approvals for innovative cancer therapies and his global regulatory strategy expertise are critical as the company navigates a competitive biotech landscape. The move highlights Vir Biotechnology's commitment to leveraging its proprietary PRO-XTEN® technology to develop next-generation therapies, positioning it for potential breakthroughs in both infectious diseases and oncology.
What we're watching
- Pipeline Execution
- How Liu's leadership will accelerate Vir Biotechnology's Phase 3 program for chronic hepatitis delta and its cancer immunotherapy pipeline.
- Regulatory Strategy
- Whether Liu's global regulatory expertise can streamline approvals for Vir Biotechnology's innovative therapies in key markets like the U.S., Europe, Japan, and China.
- Industry Trends
- The pace at which Vir Biotechnology can leverage its PRO-XTEN® masking platform to stay ahead in the competitive immuno-oncology landscape.
Related topics